Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00912873
Other study ID # Hip Concentration Study
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 2008
Est. completion date June 2009

Study information

Verified date February 2021
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a research study to determine if the concentration of local anesthetic through a catheter next to the nerves that go to the hip that is undergoing surgery, affects muscle strength and sense of touch experienced after surgery. This study is looking at the varying concentrations of local anesthetic placed through the catheter.


Description:

These results will help define the optimal concentration of local anesthetic used for continuous peripheral nerve blocks and help guide future research in this clinically-relevant area. This investigation will be a randomized, observer-masked, controlled, parallel-arm, human-subjects clinical trial. Enrollment. Subjects will be patients undergoing hip arthroplasty. Study inclusion will be proposed to eligible patients by the orthopedic surgery or anesthesia services or research coordinator/assistant within four weeks prior to surgery. If a patient desires study participation, written, informed consent will be obtained. Selection for inclusion will not be based on gender, race, or socioeconomic status. The study population of interest includes men and women of all races and socioeconomic status. Preoperative Management. Prior to surgery but following written, informed consent, subjects will have baseline endpoints measured. Patients will then have a perineural catheter placed on the operative side using standard techniques currently used at UCSD, and previously described. A 15 mL bolus of 2% mepivacaine with epinephrine (5 µg/mL) will be injected through the catheter to demonstrate correct catheter placement and provide intraoperative analgesia. Patients with a misplaced catheter indicated by a lack of sensory changes in the surgical extremity within 15 min will have their catheter replaced or be withdrawn from the study prior to randomization. The remaining patients will then be randomized to one of two treatment groups: a postoperative ropivacaine concentration of 0.1% or 0.4% ("study infusate"). Randomization will be based on computer-generated codes that will be created and maintained by the Investigational Drug Service. Randomization will be in blocks of four, and stratified by hip arthroplasty procedure (either total or resurfacing). A portable electronic infusion pump with study infusate will be attached to the perineural catheter. The basal rate and patient-controlled bolus volume will depend upon the treatment group (note that the basal rate and bolus volume differ for each concentration, but the total dose of local anesthetic is the same for each): Ropivacaine Concentration 0.1%: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h) Ropivacaine Concentration 0.4%: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h) Intraoperative Management. Patients will receive a standardized general anesthetic with an inhaled anesthetic in N2O and O2. These gasses will be titrated for a Bispectral Index of 40-60 in order to provide adequate anesthesia while minimizing postoperative recovery duration. Esmolol and hydralazine will be used to provide hemodynamic stability, and opioids administered if necessary (fentanyl in 25 µg increments). The ropivacaine infusion provided by the Investigational Drug Service will be initiated using an infusion pump attached to the perineural catheter. Just prior to emergence, IV morphine will be titrated for a respiratory rate of 12-14. Upon emergence, patients will be taken to the recovery room and then to the surgical ward. Postoperative Pain Management. For the duration of the study, all patients will receive the current usual and customary analgesics for hip arthroplasty patients at Hillcrest and Thornton hospitals. Perineural infusions will be administered per standard UCSD routine: continued administration until recommended discontinuation by the surgical service at which time the catheter is removed by the acute pain service. Outcome Measurements. We have selected measures that have established reliability and validity. Staff blinded to treatment group assignment will perform all measures and assessments. Preoperative measurements (performed prior to perineural catheter placement the day of surgery): strength of the quadriceps femoris, hip adductors, and hip flexors; and sensory level (measurement descriptions below). Postoperative measurements will be performed the day following surgery as close to 8:00-9:00 and 12:30-13:30 as possible (logistics occasionally preclude therapist evaluation at these exact hours).


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date June 2009
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Primary, unilateral hip arthroplasty - age greater than or equal to 18 years - postoperative analgesic plan includes perineural local anesthetic infusion Exclusion Criteria: - morbid obesity as defined by a body mass index greater than 40 - chronic high dose opioid use - history of opioid abuse - neuro-muscular deficit of the ipsilateral femoral nerve and/or quadriceps muscle - vulnerable populations i.e., children, pregnant women, or prisoners

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
0.1% Ropivacaine
Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
0.4% Ropivacaine
Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)

Locations

Country Name City State
United States UCSD Medical Center San Diego California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Diego

Country where clinical trial is conducted

United States, 

References & Publications (1)

Ilfeld BM, Moeller LK, Mariano ER, Loland VJ, Stevens-Lapsley JE, Fleisher AS, Girard PJ, Donohue MC, Ferguson EJ, Ball ST. Continuous peripheral nerve blocks: is local anesthetic dose the only factor, or do concentration and volume influence infusion eff — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change From Baseline in Quadriceps Femoris Maximum Voluntary Isometric Contraction (MVIC) Quadriceps femoris muscle strength evaluated using a portable, hand-held, isometric force dynamometer (MicroFET2, Lafayette Instrument Company, Lafayette, IN) to measure the maximum voluntary isometric contraction (MVIC) in a seated position. The study primary endpoint will be the difference in MVIC the morning following surgery compared with the preoperative MVIC, expressed as a percentage of the preoperative MVIC: (preop - postop ) / preop x 100. The study primary endpoint will be the difference in MVIC the morning following surgery compared with the preoperative MVIC, expressed as a percentage of the preoperative MVIC: (preop - postop ) / preop x 100.
Secondary Ambulation 100-foot Walking Test The 100-foot walking test simply measures the amount of time it takes patients to ambulate 100 feet. Patients will be allowed to slow or stop and rest during the walk, but will be asked to resume walking as soon as they feel they are able to. Day following surgery
Secondary Total Ambulation Patients will be allowed to slow or stop and rest during the walk, but will be asked to resume walking as soon as they feel they are able to and go as far as they comfortable walking. Day following surgery
Secondary Percent Change From Baseline in Hip Flexion Evaluated in the supine position using a portable, hand-held, isometric force dynamometer (MicroFET2, Lafayette Instrument Company, Lafayette, IN). The endpoint will be the difference the morning following surgery compared with the preoperative value, expressed as a percentage of the preoperative value: (preop - postop ) / preop x 100. Day following surgery
Secondary Mean Resting Pain Pain level evaluated using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain Day following surgery
Secondary Average Dynamic Pain Pain evaluated during physical therapy using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain Day following surgery
Secondary Worst Dynamic Pain The worst pain experienced during physical therapy evaluated using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain Day following surgery
See also
  Status Clinical Trial Phase
Completed NCT02275494 - The Influence of Leg Length Discrepancy After Total Hip Arthroplasty on Function and Quality of Life N/A
Completed NCT00967980 - Femoral Versus Psoas Continuous Peripheral Nerve Blocks Following Hip Arthroplasty Phase 4
Completed NCT03585647 - Anesthetic Methods and Gene Expression Profile
Not yet recruiting NCT06009432 - Efficacy of Proprioceptive Neuromuscular Facilitation Exercise Program in Total Hip Arthroplasty N/A
Completed NCT06009419 - Effectiveness of Dual Task Training in Total Hip Arthroplasty N/A
Completed NCT00921908 - Multihole or Epidural Catheter for Local Anesthetic in the Wound N/A
Completed NCT00367289 - CT for Diagnosis of Implant Stability in Revision Arthroplasty N/A
Completed NCT00253838 - A Comparison of Two Type of Stems in Revision Hip Arthroplasty N/A
Enrolling by invitation NCT04592939 - Trial of Weight Bearing Status Following Femoral Revision With Tapered, Fluted, Titanium Stems N/A
Not yet recruiting NCT03259672 - Influence of Sevoflurane and Desflurane on Postoperative Sore Throat N/A
Recruiting NCT05807828 - VR Simulation and Basic Skills in THA N/A
Terminated NCT00621530 - Effect of Spinal Ketorolac on Mechanical Hypersensitivity After a Total Hip Replacement Phase 2
Recruiting NCT04426058 - CMP vs Fascia Iliaca Block N/A
Terminated NCT02818764 - Delirium, Intraoperative Cerebral Perfusion and EEG Abnormalities After Total Hip Arthroplasty
Completed NCT00261040 - Minimally Invasive Surgery of the Hip Versus Standard Approach N/A
Completed NCT03173339 - Influence of Remifentanil on Postoperative Sore Throat in Patients Undergoing General Anesthesia N/A
Completed NCT03035435 - Fast-track Rehabilitation After Total Knee or Hip Arthroplasty N/A
Completed NCT01520961 - Functional Recovery After Partial Hip Arthroplasty: Anterior or Posterolateral Approach? N/A
Terminated NCT00934661 - Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing Phase 4
Completed NCT00226070 - Rehabilitation to Patients Over 65 Years Undergoing THA Phase 1/Phase 2